Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Kirin Brewery Co. (KRN)

  Print      Mail a friend       Annual reports

Thursday 24 March, 2005

Kirin Brewery Co.

Research Update

Kirin Brewery Co Ld
24 March 2005

                                                               March 24, 2005

                                Research into Health-promoting Lactic Acid Bacteria - 4
                                           Effectiveness of Lactobacillus KW
                                               against Atopic Dermatitis

Animal studies show greater symptomatic improvement than with Lactobacillus GG; improvement with humans also confirmed
Tokyo, March 24, 2005-Kirin Brewery Company Limited (Kirin) today announced further outcomes of ongoing research into
the health-promoting properties of Lactobacillus paracasei KW3110 (hereafter Lactobacillus KW), a lactobacteria with
high efficacy against allergies. The research is being carried out at the Central Laboratory for Key Technology in
Kanazawa ward, Yokohama City.

Building on research presented in 2004 that demonstrated the effectiveness of Lactobacillus KW1 against atopic
dermatitis using an animal model susceptible to atopic dermatitis, results of the most recent animal model study showed
that Lactobacillus KW was effective at both preventing the occurrence of atopic dermatitis and producing symptomatic
improvement in existing atopic dermatitis. The study also showed that Lactobacillus KW was more effective than
Lactobacillus rhamnosus GG (hereafter LGG), a different strain of lactobacillus that has already been shown to act
against similar skin conditions2. Moreover, a clinical trial involving patients with atopic dermatitis suggested that
Lactobacillus KW was also effective in humans.

1    As presented to the Japan Society for Bioscience, Biotechnology, and Agrochemistry (JSBBA) in March 2004
2    A group in Finland has published studies showing the effectiveness of LGG in preventing and treating atopic
     dermatitis in infants. These studies are widely known in Europe and other places.

The results of the animal model research will be presented on March 30, 2005 to the JSBBA. The results of the clinical
trial on humans will be presented on June 3, 2005 at a spring clinical conference being held by the Japanese Society of

Comparative research on more than 100 strains of lactic acid bacteria owned by Kirin Group has shown that Lactobacillus
KW has the highest anti-allergy properties. Allergies are related to lymphocytes known as Th1 and Th2. Examination of
the blood of people suffering from allergies has shown an imbalance of these two lymphocytes, with Th2 becoming
dominant. Because Lactobacillus KW has the property of improving the balance of Th1 and Th2. it does not just relieve
the symptoms of illness but improves allergic predisposition and Kirin's studies have so far demonstrated this

For the research announced today, animals susceptible to atopic dermatitis were divided into three groups. One group
was provided with a regular diet, one group was given Lactobacillus KW with its diet as a preventative, and one group
was given Lactobacillus KW after the onset of atopic dermatitis. Subsequent observation confirmed that symptoms of
atopic dermatitis were suppressed in both the pre- and post-onset groups. Next, in trials that compared Lactobacillus
KW to LGG, it was shown that Lactobacillus KW controlled symptoms to a greater degree than LGG. The trials therefore
demonstrated that Lactobacillus KW was effective against atopic dermatitis both preventatively and after onset, and
that the effect of Lactobacillus KW was greater than that of LGG.

In a further study, 84 people with symptoms of atopic dermatitis were divided into two groups. One group was provided
with Lactobacillus KW and the control group was given a placebo. Observation over 12 weeks showed a significant
improvement in symptoms such as itchiness and skin rash in the group receiving Lactobacillus KW. Comparison with the
placebo control group showed a higher degree of improvement in itchiness. The results suggest that Lactobacillus KW
functions to control atopic dermatitis not only in animals but also in humans.

Kirin is carrying out a wide range of health-related research on food products, particularly in the area of alcohol
beverages. The results of research into Lactobacillus KW will be utilized throughout the Group, and research into the
health-promoting properties of lactic acid bacteria will continue.

                                      Outline of research methodology and results

1. Characteristics of Lactobacillus KW
The beneficial effects of microbial components of lactic acid bacteria on the body are known as 'biogenics'. Since the
effects are not caused by living bacteria but by a component of bacteria, diverse applications using heat-treated
(dead) bacteria are expected.

Comparative research on more than 100 strains of lactic acid bacteria owned by Kirin Group has confirmed that
Lactobacillus KW has the highest biogenic effects in improving Th1/Th2 imbalance. Lactobacillus KW is recognized for
its role in improving hay fever and other conditions, as well as for its effect on atopic dermatitis.

2. Main research results
Animal model study 1
(1) Animals susceptible to atopic dermatitis (NC/Nga mice) were divided into three groups: one group was fed normally;
    one group was given Lactobacillus KW preventatively at approximately 10mg per day; and one group was given
    Lactobacillus KW only after developing atopic dermatitis. Inflammation on the animals' ears and heads was observed
    and scored.

(2) The preventatively dosed group showed a significant suppression of symptomatic progression compared to the group
    receiving regular feed.

(3) The group dosed after onset also showed a significant suppression of symptomatic progression.

Animal model study 2

(1) NC/Nga mice were divided into three groups: one group was fed normally; one group received approximately 10mg of
    Lactobacillus KW per day; and one group received approximately 10mg of LGG per day. Scores were monitored as per
    animal model study 1 above.

(2) A significant suppression of the progression of atopic dermatitis was observed in both groups receiving lactic acid
    bacteria, but a significantly greater effect was observed in the group receiving Lactobacillus KW. The inhibitory
    effect observed in the KW group was significantly greater than that in the LGG group.

Clinical trial on patients with atopic dermatitis

(1) 84 people with light or moderate atopic dermatitis were divided into two groups. One group received Lactobacillus
    KW (the KW group), and one group received a placebo powder (the control group). Blood samples were taken and
    clinical symptoms were assessed by a doctor every four weeks.

(2) The KW group showed significant improvement in measures such as degree of itchiness, impact on quality of life,
    skin condition, and affected skin area. The KW group demonstrated a particular improvement in degree of itchiness
    and daily quality of life compared to the control group.

(3) The results of this study suggest that Lactobacillus KW is effective at controlling the progression of atopic
    dermatitis not only in animals but also in humans.

                      This information is provided by RNS
            The company news service from the London Stock Exchange                                                                                                    

a d v e r t i s e m e n t